Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptional profiling of Ishikawa cells treated with H3B-5942, E2, or standard of care compounds

ABSTRACT: The objective of this experiment was to determine the affect of H3B-5942 treatment on global gene expression in an estrogen-deprived setting (agonist mode) and to compare to treatment with a saturated analog of H3B-5942, GDC-0810, and standard of care agents tamoxifen and fulvestrant.

ORGANISM(S): Homo sapiens

PROVIDER: GSE115608 | GEO | 2018/06/12

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcriptional profiling of MCF7 cells treated with H3B05942, E2, or standard of care compounds

Project description:The objective of this experiment was to compare the affect of H3B-5942 treatment on global gene expression and to compare to treatment with standard of care agents tamoxifen and fulvestrant.

2018-06-12 | GSE115609 | GEO

ChIP-Seq analysis of estrogen deprived MCF7 cells treated with H3B-5942 and standards of care compounds

Project description:The goal of this experiment was to interrogate the potential transcriptional impact of H3B-5942 by investigating its influence on genome-wide DNA-binding modes of ERa in MCF7 cells using chromatin immunoprecipitation followed by high-throughput DNA sequencing (ChIP-Seq). Affects of H3B-5942 on chromatin recruitment were compared to results from treatment with E2, 4-OHT, and fulvestrant.

2018-06-12 | GSE115607 | GEO

RNA-seq of HCC1428 LTED breast cancer cell line post ligand treatment

Project description:Global gene expression analysis of HCC1428-LTED (long term estrogen deprived) breast cancer cell lines was evaluated after overnight treatment with 6 selective estrogen receptor degarders (SERDs). Two gene expression signatures were identified. GDC-0810 and AZD9496 have a similar gene expression profile which is distinct from fulvestrant. SAR439859 gene expression signature clusters closely with fulvestrant. Replacing the carboxylic side chain of GDC-0810 and AZD9496 with a basic side chain of SAR439859 to make novel SERDs, GDC-SAR and AZD-SAR, respectively, shifts the gene expression signature to more closely align to that of fulvestrant. The effect of SERDs on gene expression can be used to further differentiate classes of SERDs.

2020-07-10 | GSE154058 | GEO

Transcriptional profiling of Ishikawa cells treated with H3B-5942, E2, or standard of care compounds

Project description:Transcriptional profiling of Ishikawa cells treated with H3B-5942, E2, or standard of care compounds

| PRJNA475565 | ENA

Gene expression regulation in MCF7 cells by H3B-6545, H3B-9709, Fulvestrant and Tamoxifen

Project description:Gene expression regulation in MCF7 cells by H3B-6545, H3B-9709, Fulvestrant and Tamoxifen

| PRJNA738454 | ENA

RNA-seq of breast cancer cell lines post ligand treatment I

Project description:Goal: study the impact of estrogen receptor ligands on gene expression in HR+ breast cancer cells Methods: RNA sequencing Results: Ligand 4-OH tamoxifen, a selective ER modulator (SERM), promotes transcriptional activation of ER and mimics the transcriptional effect of natural ligand E2 for a subset of ER target genes, consistently across the seven breast cell lines (MCF-7, HCC1500, MDA-MB-330, EFM-19, T-47D, BT-474, and CAMA-1). Selective ER degraders (SERD) fulvestrant and GDC-0927 on the other hand do not induce, or induce very weakly the expression of ER target genes. The effect of GDC-0810 depends on the cellular context.

2019-07-25 | GSE117942 | GEO

RNA-seq of breast cancer cell lines post ligand treatment II

Project description:Goal: study the impact of estrogen receptor ligands on gene expression in HR+ breast cancer cells Methods: RNA sequencing Results: Ligand 4-OH tamoxifen, a selective ER modulator (SERM), promotes transcriptional activation of ER and mimics the transcriptional effect of natural ligand E2 for a subset of ER target genes, consistently across the seven breast cell lines (MDA-MB-134 VI, MDA-MB-330, EFM-19, T-47D, and BT-474). Selective ER degraders (SERD) fulvestrant and GDC-0927 on the other hand do not induce, or induce very weakly the expression of ER target genes. The effect of GDC-0810 depends on the cellular context.

2019-07-25 | GSE128911 | GEO

Gene expression regulation in MCF7 cells by H3B-6545, H3B-9709, Fulvestrant and Tamoxifen

Project description:In the cellular setting, both H3B-6545 and H3B-9709 were confirmed to be non-degraders and had nearly identical impact on global gene expression changes

2022-03-15 | GSE178303 | GEO

RNA-seq and ChIP-seq in MCF7 cells treated with H3B-6545, H3B-9709, Fulvestrant and Tamoxifen

Project description:RNA-seq and ChIP-seq in MCF7 cells treated with H3B-6545, H3B-9709, Fulvestrant and Tamoxifen

| PRJNA738710 | ENA

H3B-8800, a novel oral splicing modulator, induces lethality in spliceosome mutant cancers [K562]

Project description:Genomic analyses of cancer have identified recurrent point mutations in the RNA splicing factors SF3B1, U2AF1, and SRSF2 that confer an alteration of function. Although cells bearing these mutations are preferentially dependent on wild-type (WT) spliceosome function, clinical means to therapeutically target the spliceosome do not currently exist. Here, we describe an orally available modulator of the SF3b complex, H3B-8800, which potently and selectively kills spliceosome-mutant epithelial and hematologic malignancies. The effects of H3B-8800 are entirely selective for the Sf3b complex, as evidenced by the identification of drug-resistant cells bearing mutations in Sf3b components. Although H3B-8800 modulates RNA splicing mediated by WT or cancer-associated SF3B1 mutants, its preferential effects on spliceosome-mutant cells is due to preferred retention of short, GC-rich introns, which are enriched in genes encoding a substantial number of spliceosome components. These data demonstrate the therapeutic potential of splicing modulation in spliceosome-mutant cancers.

2017-12-20 | GSE94528 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data